Physician preferences for non-metastatic castration-resistant prostate cancer treatment

Recent approvals of second-generation androgen receptor inhibitors (SGARIs) have changed the treatment landscape for non-metastatic castration-resistant prostate cancer (nmCRPC). These SGARIs have similar effi...

Source: BMC Urology - June 22, 2020 Category: Urology & Nephrology Authors: Sandy Srinivas, Ateesha F. Mohamed, Sreevalsa Appukkuttan, Marc Botteman, Xinyi Ng, Namita Joshi, Erica Horodniceanu, A. Reginald Waldeck and Stacey J Simmons Tags: Research article Source Type: research